RhumbLine Advisers
ORIC icon

RhumbLine Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

RhumbLine Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.24M Sell
92,124
-1,795
-2% -$22.4K ﹤0.01% 2144
2026
Q2 		$1.02M Buy
93,919
+14,856
+19% +$135K ﹤0.01% 2303
2026
Q1 		$1M Buy
79,063
+1,357
+2% +$15.4K ﹤0.01% 2198
2025
Q4 		$636K Sell
77,706
-4,325
-5% -$49.8K ﹤0.01% 2519
2025
Q3 		$984K Buy
82,031
+10,600
+15% +$112K ﹤0.01% 2251
2025
Q2 		$725K Sell
71,431
-17,322
-20% -$116K ﹤0.01% 2425
2025
Q1 		$495K Sell
88,753
-4,566
-5% -$39.9K ﹤0.01% 2582
2024
Q4 		$753K Buy
93,319
+4,072
+5% +$37.4K ﹤0.01% 2403
2024
Q3 		$915K Sell
89,247
-3,455
-4% -$34.2K ﹤0.01% 2308
2024
Q2 		$655K Buy
92,702
+32,402
+54% +$290K ﹤0.01% 2476
2024
Q1 		$829K Buy
60,300
+2,396
+4% +$28.5K ﹤0.01% 2356
2023
Q4 		$533K Sell
57,904
-677
-1% -$4.9K ﹤0.01% 2623
2023
Q3 		$354K Buy
58,581
+6,676
+13% +$54.7K ﹤0.01% 2831
2023
Q2 		$403K Buy
+51,905
New +$295K ﹤0.01% 2828
2022
Q2 		– Sell
-38,871
Closed -$208K – 3196
2022
Q1 		$208K Buy
38,871
+2,921
+8% +$26.3K ﹤0.01% 2749
2021
Q4 		$528K Sell
35,950
-402
-1% -$6.27K ﹤0.01% 2487
2021
Q3 		$760K Buy
36,352
+2,578
+8% +$52.3K ﹤0.01% 2352
2021
Q2 		$597K Buy
33,774
+11,287
+50% +$247K ﹤0.01% 2487
2021
Q1 		$551K Buy
22,487
+495
+2% +$15.6K ﹤0.01% 2445
2020
Q4 		$744K Buy
21,992
+13,308
+153% +$382K ﹤0.01% 2267
2020
Q3 		$217K Sell
8,684
-1,425
-14% -$33.9K ﹤0.01% 2652
2020
Q2 		$341K Buy
+10,109
New +$323K ﹤0.01% 2519

Other funds holding ORIC

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

RhumbLine Advisers's ORIC Position: Q3 2026 in Review

RhumbLine Advisers reduced its Oric Pharmaceuticals (ORIC) stake by 1.9% in Q3 2026, selling an estimated $22.4K and leaving 92,124 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2144.

RhumbLine Advisers first reported a position in ORIC in Q2 2020 and has held it in 22 quarters since. 89 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • RhumbLine Advisers held 92,124 shares of Oric Pharmaceuticals worth $1.24M as of Q3 2026.
  • RhumbLine Advisers sold 1,795 Oric Pharmaceuticals shares in Q3 2026, an estimated $22.4K.
  • Oric Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2144 holding.
  • RhumbLine Advisers first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 89 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.